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Defining the health-related quality of life (HRQoL) in 
patients suffering from the heritable blistering disease 
epidermolysis bullosa (EB) is important in assessing the 
efficacy of new treatments. The quality of life in EB ques-
tionnaire (QOLEB) is an English 17-item EB-specific 
HRQoL measurement tool. The aim of this study was to 
develop a validated and reliable QOLEB in Dutch and 
assess the HRQoL in Dutch EB patients. The QOLEB 
was translated to Dutch according to protocol. Fifty-
five adult patients across 4 EB subtypes participated. 
The QOLEB had excellant correlation with the Skin-
dex-29 (ρ
s 
= 0.86), good correlation with the SF-36 phy-
sical score (ρ
s 
= –0.75), and moderate correlation with 
the SF-36 mental score (ρ
s 
= –0.43). The discriminative 
validity between the 4 different EB subtypes was signi-
ficant (p = 0.002). The internal consistency was excellent 
(α = 0.905), and the test–retest reliability strong (ρ
s 
= 0.88). 
In conclusion, the Dutch QOLEB is a reliable and valid 
instrument for the assessment of the HRQoL in adult EB 
patients. Key words: epidermolysis bullosa; health-related 
quality of life; validation; questionnaire; assessment.
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Epidermolysis bullosa (EB) consists of a spectrum of 
heritable trauma-induced blistering diseases of skin and 
mucous membranes (1). Many subtypes exist, and their 
clinical severity is variable, ranging from an occasional 
palmoplantar blister to childhood lethality (1). The 
health-related quality of life (HRQoL) is the impact of a 
disease on the physical, psychological, and social health 
of a patient (2). Defining  HRQoL in EB patients is im-
portant in patient care and management (3). Furthermore, 
in recent years more focus has been placed on finding 
specific treatments for EB and measuring HRQoL can 
help in assessing the efficacy of these new treatment mo-
dalities (4, 5). Also, measuring and comparing HRQoL 
to other diseases can help assign funding to this rather 
unknown and rare disorder (4, 6). Measuring HRQoL 
is complicated by the wide range of phenotypes in EB, 
which all have their own clinical severity (3). Several stu-
dies have focused on qualitatively describing the impact 
of EB on patients’ lives (7–11). Quantitative measure-
ment of HRQoL has been performed using both generic 
and dermatology-specific instruments in EB patients 
(6, 12–15). However, due to ceiling effects and content 
validity issues of these instruments, the accuracy of the 
measurements is questionable. It has been hypothesised 
that, especially in the more severe EB subtypes, there has 
been an overestimation of the HRQoL (3). To overcome 
these problems, Frew et al. (3) developed and validated an 
EB-specific HRQoL measurement tool for older children 
and adults that can be used across all EB subtypes, called 
the QOLEB (quality of life in EB). Translation of the 
QOLEB, which was created and validated in English in 
Australia, to other cultures and languages may provide 
reliable comparisons of HRQoL in EB and the efficacy of 
clinical interventions across different countries (3). The 
aim of this study was to develop a validated and reliable 
QOLEB in Dutch, and to assess HRQoL in Dutch EB 
patients. 
MATERIALS AND METHODS
This study was performed at the Center for Blistering Diseases 
at the University Medical Center Groningen, which is the single 
national referral centre for EB in the Netherlands. Ethical 
approval was granted by the Medical Ethical Committee of the 
University Medical Center Groningen in the Netherlands. A sig-
ned consent form was obtained from all participating patients. 
Study measurement tools 
The English QOLEB is a validated and reliable adult EB-
specific HRQoL tool consisting of a 17-item questionnaire, and 
it was developed by 2 of the authors (JWF and DFM) (3). The 
QOLEB measures 2 factors: functioning (questions 1–7, 9–10, 
12–13, 15) and emotions (question 8, 11, 14, 16–17). For each 
question 4 optional answers exist that are scored from 0 to 3 
points, in which a higher score represents a worse HRQoL. The 
functioning scale ranged from 0–36, the emotions scale from 
0–15, and the overall scale from 0–51 points. Recently proposed 
banding techniques by J.W.F and D.F.M. for the overall severity 
of the QOLEB score based upon the data reported in the original 
QOLEB validation are as follows: very mild (0–4 points), mild 
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(5–9 points), moderate (10–19 points), severe (20–34 points), 
and very severe (35–51 points) (3). 
The Short Form-36 (SF-36) is a 36-item generic HRQoL 
instrument measuring 8 scales: physical functioning (PF, li-
mitations in physical activities because of health problems), 
role-physical (RP, limitations in usual role activities because 
of physical health problems), bodily pain (BP, limitations 
and severity of pain), general health (GH, perceptions of the 
general health), vitality (VT, energy and fatigue experienced 
due to health problems), social functioning (SF, limitations in 
social activities because of physical or emotional problems), 
role-emotional (RE, limitations in usual role activities because 
of emotional problems), and mental health (MH, psychological 
distress and well-being) (16). Each scale is normalised to scores 
from 0 to 100 points, in which a higher score represents a better 
HRQoL (contrary to QOLEB). Two summary scales have been 
developed: the physical component summary (PCS) and the 
mental component summary (MCS) (17). The SF-36 has been 
translated and validated to Dutch, and age-and gender norm 
values are available for the Dutch population (18). 
The Skindex-29 is a 30-item validated and reliable dermatolo-
gy-specific HRQoL instrument for adults, measuring 3 factors: 
emotions (n = 10), functioning (n = 12) and symptoms (n = 7) 
(19–21). Each item can be answered on a 5-point scale ranging 
from “never” to “all the time”, that are scored from 0 to 100 
points. A higher score represents a worse HRQoL (similar to 
QOLEB). The overall Skindex-29 score indicates that the skin 
disease has very little (< 5 points), mild negative (6–17 points), 
moderate (18–36 points), and severe (> 37 points) effect on the 
HRQoL. Different intervals are used for the domains separately 
but with the same classification: emotions (< 5; 6–24; 25–49; 
> 50), functioning (< 3; 4–10; 11–32; > 33), and symptoms 
(< 3; 4–10; 11–25; 26–49; and >50 for extremely severe) (22). 
The Skindex-29 has been translated to Dutch using a standard 
protocol (12).
Translation of the QOLEB to Dutch
Forward translation of the QOLEB to Dutch was performed 
by an independent qualified translator. The questionnaire 
was discussed by experts in EB (W.Y.Y. and M.F.J), who are 
native speakers in Dutch and fluent in English. There were no 
conceptual changes made. Content validity was obtained by 
back-translation to English by a different independent qualified 
translator to make sure the translated Dutch QOLEB conveys the 
same meaning as the English QOLEB. The back-translation was 
assessed by the writers of the manuscript. The Dutch QOLEB 
is given in Appendix S11. 
Recruitment and design
From the Dutch EB registry, adult patients across a range of 
subtypes were included to participate in this study. The patients 
were classified into 4 main EB subtypes: EB simplex (EBS), 
junctional EB (JEB), dominant dystrophic EB (DDEB), and 
recessive dystrophic EB (RDEB). Inclusion criteria were that 
patients were native speakers of Dutch, and that they had an 
age of ≥ 18 years. The selected patients received an informa-
tion letter concerning the design, relevance and main goal of 
the study. A week after receiving this letter, the patients were 
given further oral information over the telephone and were in-
vited to participate in the study. The patients that were willing 
to participate received the first Dutch QOLEB, Skindex-29, 
and SF-36. They were requested to complete and return these 
questionnaires. Four weeks after completing the questionnai-
res, all patients were asked to complete and return the same 
questionnaires for a second time. When required and possible, 
data were clarified over the telephone. 
Analysis
Floor and ceiling effects for the individual items were conside-
red when ≥ 80% of the participants scored the highest or lowest 
possible scores in the first QOLEB. 
The respondent burden was assessed by the self-reported 
completion time of the first QOLEB, and was considered brief 
if < 15 min. 
The convergent validity was assessed by calculating Spear-
man’s rho correlation coefficient (ρs) between the overall score 
of the first QOLEB and the overall score of the Skindex-29, 
and the MCS and PCS score of the SF-36 (12). A ρs of ≥ 0.7 
was considered as acceptable, and ≥ 0.8 as excellent. The 
discriminative validity was calculated between the 4 main EB 
subtypes using an analysis of variance (ANOVA). A p < 0.05 
was considered as statistically significant.
The internal consistency and construct validity of the Dutch 
QOLEB was measured with the Cronbach alpha (α) using the 
data from the first QOLEB. An α of ≥ 0.7 was considered as 
acceptable, ≥ 0.8 as good, and ≥ 0.9 as excellent. The degree of 
test-retest reliability was estimated by ρs between the overall 
scores of the QOLEB questionnaire at the first and second time. 
A ρs of ≥0.7 was considered as acceptable, and ≥ 0.8 as excellent.
Mean values and standard deviations (SD) were calculated for 
the scores of all study measurement tools and compared using 
ANOVA with a Bonferroni post hoc test comparing between the 
disease groups. A p ≤ 0.05 was considered statistically significant.
RESULTS
Study population
As of 1st January 2011, 184 adult EB patients from the 
Dutch EB Registry met the inclusion criteria and were 
eligible for participation. We randomly selected 103 
patients to be included in the study. Of the 103 patients 
that were invited by the information letter to participate 
in the study, 75 patients were willing to co-operate 
(response rate 73%). The remaining 28 patients did not 
want to take part in the study or could not be reached 
by telephone. Of the 75 patients, 55 were included in 
the study (response rate 73%). The remaining 20 pa-
tients were excluded due to unreturned questionnaires 
or incomplete questionnaires. 
The characteristics of the study population and drop 
outs, split to EB subtype, are shown in Table SI1. Of the 55 
included patients, 51% were male and 49% were female. 
The mean age was 47.6 years (SD ± 17.1) with a range of 
19–85 years. The distribution among EB types was: EBS 
29 (53%), JEB 8 (15%), DDEB 13 (24%), and RDEB 5 
(9%) patients. All patients were of Dutch ethnicity, except 
for one Korean, one Surinamese, and one Turkish patient. 
All patients were native speakers of Dutch. 
Some characteristics of QOLEB
Floor effects were seen in 4 of the 17 items: item 2 
(bathing or showering; 82%), item 4 (writing; 84%), 1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-1758
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item 5 (eating; 80%), and item 12 (modifying house; 
82%). No ceiling effects were present in the 17 items 
(Table SII1). 
The respondent burden of time for the QOLEB was 
brief, with a mean of 8.2 min (SD ± 5). 
The results of the validity tests are summarised in 
Table SIII1. The content validity was addressed through 
the forward-backward translation of the QOLEB to 
Dutch, which showed no validity issues. The QOLEB 
correlated well with the SF-36 PCS score (ρs = –0.75), 
and extremely well with the Skindex-29 (ρs = 0.86). Be-
tween the SF-36 MCS score and the QOLEB a moderate 
correlation was seen (ρs = –0.43). A significant discri-
minative validity between the 4 different EB subtypes 
was seen (p = 0.002). 
The results of the reliability tests are summarised in 
Table SIII1. The QOLEB showed an excellent internal 
consistency and construct validity (α = 0.905). Further-
more, the internal consistency and construct validity in 
the separate EB subtypes was good to excellent (range 
α = 0.85–0.94). The test–retest reliability of the QO-
LEB was strong (ρs = 0.88) after a mean of 57 (SD ± 24) 
days. Also, the test–retest reliability in the separate EB 
subtypes was good to excellent (range ρs = 0.82–0.98).
Assessment of QoL 
Dutch QOLEB. The results of the Dutch QOLEB are 
listed in Table I. Overall, the Dutch QOLEB mean 
scores were lower than the ones reported in the ori-
ginal QOLEB study, which included more patients 
(n = 111) and more severe EB patients (8 JEB and 16 
RDEB) (3). Females had a lower HRQoL than males, 
although these differences never reached statistical 
significance. The milder EB subtypes EBS and DDEB 
both showed a better HRQoL in all scales, compared 
to the more severe RDEB and JEB. These differences 
reached a discriminative validity for functioning and 
overall score, but not for the emotions scale (Table I). 
According to the categorisation of the overall QOLEB 
score, the Dutch EBS and DDEB cohorts were mildly 
affected, and the Dutch JEB and RDEB cohorts were 
moderately affected. None of the patients were very 
severely affected, and only 4% were severely affected 
(Table II), whereas in the original QOLEB score, se-
veral patients with RDEB and JEB were in this range. 
The results of the 17 individual QOLEB items are 
listed in Table SII1. EB made 71% of the patients feel 
frustrated, 36% embarrassed, 31% depressed, 27% 
uncomfortable, and 51% anxious or worried. EB af-
fected patients in their relationship with their friends 
(31%) and family (25%), although in most patients only 
a small effect was noticed. Only 16% of all patients 
were pain-free, while 9% experienced constant pain. 
Twenty percent of the patients were affected in their 
eating ability, and 19% needed some sort of assistance 
with bathing or showering. Difficulties in writing were 
especially prominent in RDEB, with 60% of the patients 
finding it easier to type than write. Almost all patients 
were affected in their involvement in sports (95%), 
with 62% needing to avoid some or all sports. Although 
49% of all patients were affected at least a little in their 
ability to move around at home, patients of the JEB and 
RDEB subtypes were affected most severely. JEB and 
RDEB patients also had to make the most modifications 
in their house. Around 38–40% of the JEB and RDEB 
patients were markedly or severely affected in their 
ability to move outside their house, and 40% of all EB 
patients were affected in their ability to go shopping. 
Of all patients, 33% were financially affected by their 
EB, and 11% were greatly or severely affected. 
Short Form-36
The results of the SF-36 are summarised in Table SIV1. 
EB had a greater impact on the HRQoL in females, al-
though no significant differences were found. On all SF-
36 scales except for VT, RE and MCS, JEB and RDEB 
patients had a lower HRQoL score compared to EBS 
and DDEB patients, reaching statistical significance 
in the PF scale between EBS and JEB (p = 0.025). In 
comparison to gender- and age-matched Dutch norma-
tive values, all EB subtypes had a lower HRQoL score 
on the PCS scale, while they were comparable on the 
MCS scale (Fig. 1). Floor effects were seen in item 3j 
(limitations in bathing or dressing; 84%), and item 5a 
(cutting down on the amount of time spent on work or 
Table II. Banding of the Dutch Quality of life in epidermolysis 
bullosa (EB) results by EB subtypes
EBS 
n = 29 
n (%)
JEB 
n = 8 
n (%)
DDEB 
n = 13 
n (%)
RDEB 
n = 5 
n (%)
Total 
n = 55 
n (%)
Very mild: 0–4 points 8 (28) 0 (0) 5 (38) 1 (20) 14 (25)
Mild: 5–9 points 12 (41) 1 (13) 2 (15) 1 (20) 16 (29)
Moderate: 10–19 points 8 (28) 6 (75) 6 (46) 3 (60) 23 (42)
Severe: 20–34 points 1 (3) 1 (13) 0 (0) 0 (0) 2 (4)
Very severe: 35–51 points 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
EBS: EB simplex; JEB: junctional EB; DDEB: dominant dystrophic EB; 
RDEB: recessive dystrophic EB.
Table I. Quality of life in epidermolysis bullosa (EB) questionnaire 











All 55 7.3 ± 5.4 2.4 ± 2.0 9.6 ± 6.9
Male 28 7.0 ± 5.1 2.0 ± 1.8 9.0 ± 6.3
Female 27 7.5 ± 5.8 2.7 ± 2.2 10.2 ± 7.5
EB subtype








Junctional EB 8 11.3 ± 5.0 3.9 ± 1.8 15.1 ± 6.4
Dominant dystrophic EB 13 5.2 ± 3.3 2.2 ± 2.0 7.3 ± 5.1
Recessive dystrophic EB 5 13.4 ± 5.4 3.2 ± 2.4 16.6 ± 11.7
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other activities due to emotional problems in the last 4 
weeks; 84%). There were no ceiling effects. 
Skindex-29
The results of the Skindex-29 are shown in Table SV1. 
On all Skindex-29 scales, females had a lower HRQoL 
score compared to males (no significance). JEB and 
RDEB had a lower HRQoL score compared to EBS and 
DDEB in the functioning and symptoms scale, reaching 
statistical significance in the functioning component 
between EBS and JEB (p = 0.022). RDEB had the best 
HRQoL on the emotions scale, while JEB had the lo-
west. There were no observed floor or ceiling effects. 
According to the Skindex-29 categorisation, EBS, 
DDEB and RDEB had a moderate effect, while JEB 
had a severe effect on the HRQoL score. The greatest 
effect was seen on the symptom scale, in which EBS 
had a severe effect, and JEB, DDEB, and RDEB had 
an extremely severe effect on the HRQoL. Analysis 
of the individual Skindex-29 items, showed that in the 
symptoms scale, 31% of the patients answered ‘often’ 
or ‘all the time’ to the item “My skin condition burns 
or stings”, 33% to “My skin itches”, 31% to “My skin 
is irritated”, 51% to “My skin is sensitive”, and 20% to 
“My skin condition bleeds”. When measuring function, 
20% of the patients answered ‘often’ or ‘all the time’ to 
the item “My skin condition affects how well I sleep”, 
22% to “My skin condition interferes with my sex life”, 
and 24% to “My skin condition makes me tired”. 
DISCUSSION
In this study, we have developed an EB-specific HRQoL 
measurement tool for Dutch patients by translating 
and validating the QOLEB into Dutch and Dutch EB 
population, respectively. A total of 55 adult patients 
across all 4 subtypes (EBS, JEB, DDEB, and RDEB) 
have participated to test the reliability and validity of 
the Dutch QOLEB. A weakness of our study is the small 
sample size for the more severe EB subtypes. Floor ef-
fects were present in 4 items, indicating that only a few 
patients had limitations in bathing/showering, writing, 
eating and needing to modify their house, suggesting 
a poor discriminative value for these items. However, 
the distribution of our patient population, in which 76% 
suffered from the milder EB (EBS and DDEB), and 
only 24% from the more severe EB (JEB and RDEB) 
subtypes, contributed to these floor effects. This might 
also explain the lack of ceiling effects seen in the SF-36 
and Skindex-29. The Dutch QOLEB is a reliable tool, 
although the high internal consistency (α = 0.905) does 
suggest some item redundancy. However, this was also 
seen in the validation of the original QOLEB (α = 0.931). 
The Dutch QOLEB appears to be a valid instrument. 
The assessment of the convergent validity was per-
formed with the Skindex-29 and SF-36, as they have 
been proven to be the generic and dermatology-specific 
HRQoL instruments of choice for dermatological di-
seases (12). A good convergent validity was seen with 
the Skindex-29 and the physical aspects of the SF-36, 
but not for the mental aspects of the SF-36. However, 
we used a standard protocol translated Skindex-29, 
which is not validated. The DLQI was not chosen to 
test the convergent validity, as it investigates the effects 
of parameters “in the past week”. As EB is a lifelong 
disease the impact on the past week is minimal, leading 
to ceiling effects and content validity issues (3). The dis-
criminative validity was significant (p = 0.002), and the 
Dutch QOLEB was also able to discriminate the severe 
subtypes RDEB and JEB from the milder subtypes EBS 
and DDEB. The advantage of the Dutch QOLEB over 
the Skindex-29 is that in the former differences were 
seen in the different disease groups, making the Dutch 
QOLEB a better discriminating questionnaire. In the 
Dutch QOLEB significant differences were seen on the 
functioning and overall scale, but not on the emotions 
scale, suggesting one of 3 explanations: either that the 
mental burden of EB is similar in milder and more 
severe subtypes, that patients with more severe EB 
subtypes have acquired emotional resilience due to the 
severe impact of living with EB, or that the QOLEB is 
not appropriate to distinguish between emotions. Such 
decreased prevalence of emotional burden is also seen 
with results from a study by Margari et al. (13), who 
found that 80% of EB patients experienced sub-thres-
hold psychiatric symptoms, in particular depression, 
anxiety, and behaviour disturbances, but that there was 
no close correlation between these symptoms and the 
clinical severity of EB (13). Emotional resilience was 
not explored by Margari et al. (13) but has been propo-
sed by Frew et al. (3) to explain the lack of consistent 
quantitative data regarding emotional burden in EB. 
Fig. 1. Epidermolysis bullosa (EB) Short Form-36 scores compared to 
gender- and age-matched Dutch normative values. EBS: EB simplex; 
JEB: junctional EB; DDEB: dominant dystrophic EB; RDEB: recessive 
dystrophic EB; PF: physical functioning; RP: role-physical; BP: bodily 
pain; GH: general health; VT: vitality; SF: social functioning; RE: role-
emotional; MH: mental health; PCS: physical component summary; MCS: 
mental component summary.
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A complicating factor in evaluating the discriminative 
factor in EB is the clinical variety and severity within 
the 4 major subtypes (1). In our study, many patients 
with a milder “minor” subtype have been included; 69% 
of the EBS patients suffered from the milder EBS-loc, 
50% of the JEB patients were diagnosed with the less 
severe JEB-nH loc, 46% of the DDEB patients had 
the less severe DDEB-pt and DDEB-ac, and only 20% 
of the RDEB patients suffered from the more severe 
RDEB-sev gen. This suggests that the HRQoL in our 
EB cohort might be overestimated. 
The results of the HRQoL assessment in our EB po-
pulation are in concordance with a recent publication 
of Tabolli et al. (15), who measured the HRQoL of the 
Italian EB population with different tools, including the 
Skindex-29 and SF-36. In this study it was concluded 
that EB has the greatest impact in patients with a higher 
perceived disease severity, with a larger skin involve-
ment, with a higher psychological distress measured by 
the General Health Questionnaire-12, and in females 
(15). The latter was also seen in our cohort, in which 
females had a lower HRQoL in both the functioning/
physical as in the emotional/mental domains measured 
with the QOLEB, Skindex-29, and SF-36. Similar to 
our Skindex-29 and SF-36 results, Tabolli et al. (15) 
showed that patients suffering from JEB and RDEB-sev 
gen have the lowest HRQoL, but that no statistically 
significant differences were seen among the various 
subtypes. This indicates that the Skindex-29 and SF-
36 have a poorer discriminative value compared to the 
QOLEB. In our study population, a greater variation in 
the SD was seen in the Skindex-29 and SF-36 compared 
to the QOLEB, which suggests a higher interpersonal 
variation per subtype in the first 2 questionnaires. Our 
comparison of the SF-36 values to the normal popula-
tion are also in concordance with Tabolli et al. (15), in 
which the PCS scale shows lower values compared to 
a normal population, while the values in the MCS scale 
are quite similar to that of the normal population: EB 
patients overall seem to be as happy (or unhappy) as 
all other people.
Horn & Tidman (14) assessed the HRQoL of EB pa-
tients living in Scotland using the dermatology-specific 
questionnaire Dermatology Life Quality Index (DLQI) 
(14). They showed that the impairment in HRQoL in 
patients with RDEB-sev gen exceeded those of any skin 
disorder previously assessed. The effects of EBS and 
other subtypes of DEB were similar to that of modera-
tely severe psoriasis and eczema (14). Comparison of 
our SF-36 results with other dermatological diseases 
(Fig. S11) (23–27), shows that on the PCS scale JEB 
and RDEB have one of the worst recorded HRQoL 
score, only to be surpassed by psoriatic arthritis (26). 
EBS has a HRQoL score similar to atopic dermatitis, 
and DDEB similar to psoriasis (26). On the MCS scale, 
DDEB and RDEB have the best recorded HRQoL score, 
while EBS scores similar to occupational contact der-
matitis, and JEB to psoriasis and hand eczema (25, 26). 
In the comparison of the Skindex-29 results with other 
dermatological diseases (Fig. S21) (28–34), the effect of 
EBS is comparable to psoriasis on the functioning and 
symptoms scale (33). On these scales, RDEB and JEB 
have the greatest recorded impairments in HRQoL after 
Hailey-Hailey disease (31). DDEB is only surpassed by 
Hailey-Hailey disease and pruritus on the symptoms 
scale (30, 31). In functioning, the effect of DDEB is 
comparable to cutaneous T-cell lymphoma (29). On the 
emotions scale RDEB and EBS are similarly affected 
as urticaria, DDEB as connective tissue diseases, and 
JEB as psoriasis and lichen planus (33). However, the 
accuracy of these comparisons might be limited due to 
the small patient numbers in our JEB and RDEB cohort.
In conclusion, we have shown that the Dutch version 
of the QOLEB is a reliable, valid, and brief instrument 
for the assessment of HRQoL in adult EB patients. 
The responsiveness of the Dutch QOLEB has not been 
assessed, and future research should be performed to 
evaluate this. Also, future development and validation 
of a QOLEB for children would be of great value. 
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